Association between the fatty liver index and risk of type 2 diabetes in the EPIC-Potsdam study

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Jäger, Susanne ^a,b   Jacobs, Simone ^a,b   Kröger, Janine ^a,b   Stefan, Norbert ^b,c   Fritsche, Andreas ^b,c   Weikert, Cornelia ^a,d   Boeing, Heiner ^a   Schulze, Matthias B ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BODY MASS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATTY LIVER; FATTY LIVER INDEX; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK ASSESSMENT; WAIST CIRCUMFERENCE; COMPLICATION; DIABETES MELLITUS, TYPE 2; GERMANY; MIDDLE AGED; RISK FACTOR;

CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84930638540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124749     Document Type: Article

References (60)

1. LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014; 48: 467-473. doi: 10.1097/MCG.0000000000000116 PMID: 24921212
2. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2: 901-910. doi: 10.1016/S2213-8587(14)70032-4 PMID: 24731669
3. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008; 31: 165-169. PMID: 17934148
4. Sung KC, Wild SH and Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013; 98: 3637-3643. doi: 10.1210/jc.2013-1519 PMID: 23873989
5. Wieckowska A and Feldstein A. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008; 28: 386-395. doi: 10.1055/s-0028-1091983 PMID: 18956295
6. Piccinino F, Sagnelli E, Pasquale G and Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2: 165-173. PMID: 3958472
7. Sahani DV and Kalva SP. Imaging the liver. Oncologist. 2004; 9: 385-397. PMID: 15266092
8. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33. PMID: 17081293
9. Kahl S, Strassburger K, Nowotny B, Livingstone R, Kluppelholz B, Kessel K, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One. 2014; 9: e94059. doi: 10.1371/journal.pone.0094059 PMID: 24732091
10. Balkau B, Lange C, Vol S, Fumeron F and Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010; 10: 56. doi: 10.1186/1471-230X-10-56 PMID: 20529259
11. Jung CH, Lee WJ, Hwang JY, Yu JH, Shin MS, Lee MJ, et al. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. Diabet Med. 2013; 30: 428-435. doi: 10.1111/dme.12104 PMID: 23278318
12. Boeing H, Korfmann A and Bergmann MM. Recruitment Procedures of EPIC-Germany. Ann Nutr Metab. 1999; 43: 205-215. PMID: 10592369
13. Boeing H, Wahrendorf J and Becker N. EPIC-Germany-A source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999; 43: 195-204. PMID: 10592368
14. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, et al. Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes. Diabetes. 2008; 57: 2762-2767. doi: 10.2337/db08-0538 PMID: 18633113
15. Kroke A, Bergmann M, Lotze G, Jeckel A, Klipstein-Grobusch K and Boeing H. Measures of quality control in the German component of the EPIC study. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999; 43: 216-224. PMID: 10592370
16. Klipstein-Grobusch K, Georg T and Boeing H. Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol. 1997; 26 Suppl 1: S174-180. PMID: 9126545
17. Brandstetter BR, Korfmann A, Kroke A, Becker N, Schulze MB and Boeing H. Dietary habits in the German EPIC cohorts: food group intake estimated with the food frequency questionnaire. Ann Nutr Metab. 1999; 43: 246-257. PMID: 10592373
18. Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG and Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008; 31: 1138-1143. doi: 10.2337/dc07-2159 PMID: 18346992
19. Enzenbach C, Kröger J, Zietemann V, Jansen EH, Fritsche A, Doring F, et al. Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein and adiponectin in middle-aged German women and men. Eur J Nutr. 2011; 50: 625-636. doi: 10.1007/s00394-011-0169-4 PMID: 21301856
20. Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502. PMID: 4337382
21. Jacobs S, Kröger J, Floegel A, Boeing H, Drogan D, Pischon T, et al. Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPIC-Potsdam Study. Am J Clin Nutr. 2014; 100: 891-900. doi: 10.3945/ajcn.113.080317 PMID: 25057154
22. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A and Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2006; 84: 427-433. PMID: 16895894
23. Bergmann MM, Jacobs EJ, Hoffmann K and Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur J Epidemiol. 2004; 19: 411-416. PMID: 15233312
24. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986; 73: 1-11.
25. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982; 69: 239-241.
26. Bergmann MM, Rehm J, Klipstein-Grobusch K, Boeing H, Schütze M, Drogan D, et al. The association of pattern of lifetime alcohol use and cause of death in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Int J Epidemiol. 2013; 42: 1772-1790. doi: 10.1093/ije/dyt154 PMID: 24415611
27. Lin DY, Fleming TR and De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997; 16: 1515-1527. PMID: 9249922
28. Wacholder S, Gail MH, Pee D and Brookmeyer R. Alternative variance and efficiency calculations for the case-cohort design. Biometrika. 1989; 76: 117-123.
29. Hoffmann K, Pischon T, Schulz M, Schulze MB, Ray J and Boeing H. A statistical test for the equality of differently adjusted incidence rate ratios. Am J Epidemiol. 2008; 167: 517-522. doi: 10.1093/aje/kwm357 PMID: 18230678
30. Lange T, Vansteelandt S and Bekaert M. A simple unified approach for estimating natural direct and indirect effects. Am J Epidemiol. 2012; 176: 190-195. doi: 10.1093/aje/kwr525 PMID: 22781427
31. Lange T, Rasmussen M and Thygesen LC. Assessing natural direct and indirect effects through multiple pathways. Am J Epidemiol. 2014; 179: 513-518. doi: 10.1093/aje/kwt270 PMID: 24264291
32. Pearl J. Direct and indirect effects. In: Proceedings of the Seventeenth conference on Uncertainty in artificial intelligence. San Francisco, CA, USA: Morgan Kaufmann; 2001. pp. 411-420.
33. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA and Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol. 2003; 13: 15-21. PMID: 12587609
34. Shibata M, Kihara Y, Taguchi M, Tashiro M and Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007; 30: 2940-2944. PMID: 17666460
35. Kim CH, Park JY, Lee KU, Kim JH and Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008; 25: 476-481. doi: 10.1111/j.1464-5491.2008.02410.x PMID: 18346164
36. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T and Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010; 25: 352-356. doi: 10.1111/j.1440-1746.2009.05998.x PMID: 19817963
37. Sung KC and Kim SH. Interrelationship between Fatty Liver and Insulin Resistance in the Development of Type 2 Diabetes. J Clin Endocrinol Metab. 2011; 96: 1093-1097. doi: 10.1210/jc.2010-2190 PMID: 21252243
38. Sung KC, Jeong WS, Wild SH and Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012; 35: 717-722. doi: 10.2337/dc11-1853 PMID: 22338098
39. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013; 44: 115-120. doi: 10.1016/j.arcmed.2013.01.007 PMID: 23398788
40. Chang Y, Jung HS, Yun KE, Cho J, Cho YK and Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. 2013; 108: 1861-1868. doi: 10.1038/ajg.2013.349 PMID: 24100261
41. Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2013; 28: 142-147. doi: 10.1111/j.1440-1746.2012.07264.x PMID: 22989165
42. Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013; 33: 1406-1412. doi: 10.1111/liv.12200 PMID: 23656177
43. Park SK, Seo MH, Shin HC and Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013; 57: 1378-1383. doi: 10.1002/hep.26183 PMID: 23213066
44. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009; 49: 1537-1544. doi: 10.1002/hep.22845 PMID: 19291789
45. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168: 1609-1616. doi: 10.1001/archinte.168.15.1609 PMID: 18695074
46. Kantartzis K, Machann J, Schick F, Fritsche A, Haring HU and Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010; 53: 882-889. doi: 10.1007/s00125-010-1663-6 PMID: 20099057
47. Feller S, Boeing H and Pischon T. Body mass index, waist circumference, and the risk of type 2 diabetes mellitus: implications for routine clinical practice. Dtsch Arztebl Int. 2010; 107: 470-476. doi: 10.3238/arztebl.2010.0470 PMID: 20644701
48. Lazo M and Clark J. The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective. Semin Liver Dis. 2008; 28: 339-350. doi: 10.1055/s-0028-1091978 PMID: 18956290
49. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178: 38-45. doi: 10.1093/aje/kws448 PMID: 23703888
50. Stefan N and Haring HU. The metabolically benign and malignant fatty liver. Diabetes. 2011; 60: 2011-2017. doi: 10.2337/db11-0231 PMID: 21788578
51. Langsted A, Freiberg JJ and Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008; 118: 2047-2056. doi: 10.1161/CIRCULATIONAHA.108.804146 PMID: 18955664
52. Kim JH, Kwon SY, Lee SW and Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int. 2011; 31: 1600-1601. doi: 10.1111/j.1478-3231.2011.02580.x PMID: 22093336
53. Koehler EM, Schouten JNL, Hansen BE, Hofman A, Stricker BH and Janssen HLA. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11: 1201-1204. doi: 10.1016/j.cgh.2012.12.031 PMID: 23353640
54. Meffert PJ, Baumeister SE, Lerch MM, Mayerle J, Kratzer W and Völzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014; 109: 1404-1414. doi: 10.1038/ajg.2014.155 PMID: 24957156
55. Siegert S, Yu Z, Wang-Sattler R, Illig T, Adamski J, Hampe J, et al. Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoS One. 2013; 8: e76813. doi: 10.1371/journal.pone.0076813 PMID: 24130792
56. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012; 32: 902-910. doi: 10.1111/j.1478-3231.2012.02781.x PMID: 22435761
57. Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, et al. The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatol Int. 2012; 7: 592-599.
58. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011; 54: 1082-1090. doi: 10.1002/hep.24452 PMID: 21618575
59. Strauss S, Gavish E, Gottlieb P and Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol. 2007; 189: W320-323. PMID: 18029843
60. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J and Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51: 433-445. doi: 10.1016/j.jhep.2009.05.023 PMID: 19604596